Search results will open in a new window on TMXMoney.com.

Exchange Bulletin

HLS Therapeutics Inc. (HLS) To Trade On Toronto Stock Exchange


February 5, 2019
Issuer: HLS Therapeutics Inc. ("HLS")
Security: Common shares (the "Shares")
Symbol: HLS
Number of securities issued and outstanding: 27,295,346 Shares
Number of securities reserved for issuance: 5,289,386 Shares
Listing category: Industrial, Non-Exempt Issuer
Trading currency: CDN$
Listing and posted for trading date: February 7, 2019 (at the opening)
Other market(s): The Shares have been listed on TSX Venture Exchange ("TSXV") under their current form since March 14, 2018 and trade under the symbol "HLS". The Shares will be delisted from TSXV on February 7, 2019 upon commencement of trading on Toronto Stock Exchange.
Temporary market maker: Mackie Research Capital Corp.
Security ownership registration: Direct Registration System
Investor relations: Dave Mason Loderock Advisors Inc. (416) 247-9652 Dave.mason@loderockadvisors.com Bettina Filippone Renmark Financial Communications Inc. (416) 644-2020 bfilippone@renmarkfinancial.com
Incorporation: Business Corporations Act (Ontario)
Fiscal year end: December 31
Nature of business: HLS is a Canada-based North America-focused specialty pharmaceutical company focused on commercializing clinically differentiated pharmaceutical products in the specialty central nervous system and cardiovascular markets.
Transfer agent and registrar: Computershare Investor Services at its principal office in Toronto.
Normal Course Issuer Bid Through the facilities of TSX or alternative Canadian trading systems up to 1,371,495 Shares during the period commencing May 18, 2018 to May 17, 2019, representing approximately 5% of HLS's issued and outstanding shares. (There were 134,600 Shares purchased to date on TSXV.)
Dividends: On August 15, 2018, HLS established a dividend policy to pay quarterly dividends of $0.05 per Share. HLS' dividend policy will be reviewed from time to time by the board of directors in the context of HLS' earnings, financial condition and other relevant factors.
Sponsorship: GMP Securities L.P.
TSX contact: Chris Birkett, Director, Toronto Stock Exchange